Meeting
2016 ASCO Quality Care Symposium
Compliance with National Comprehensive Cancer Network guidelines for antiemesis in cisplatin regimens.
Authors
Terri P. Wolf
UC Davis Health Syst, Carmichael, CA
Terri P. Wolf, Dana Ann Little
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Science of Quality
Track
Cost, Value, and Policy in Quality,Practice of Quality,Science of Quality
Sub Track
Quality Measurement
Citation
J Clin Oncol 34, 2016 (suppl 7S; abstr 280)
DOI
10.1200/jco.2016.34.7_suppl.280
Abstract #
280
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The equivalency study of novel current standard 3-drugs combination regimen (ondansetron, dexamethasone and olanzapine) to netupitant containing regimen for preventing high dose cisplatin induce nausea and vomiting treatment, double blind placebo control trial.
First Author: Chalermchai Lertanansit
Poster
2011 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.
First Author: J. L. Vardy
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2023 ASCO Annual Meeting
Guideline-concordant use of olanzapine as part of a 4-drug antiemetic regimen for high emetic risk chemotherapy across the state of Michigan.
First Author: Ashley Bowen